Live Tracker
Biotech M&A Tracker 2026
Every control transaction in 2026 — target, acquirer, deal value, premium-to-unaffected, and investor-grade rationale.
52 deals. ~$159.7B tracked.
Last updated 12 July 2026
Research Hub
Live deal trackers & research reports
Reference tools for biotech and biopharma investors — updated regularly.
Live Trackers
Other Reports
30-Jun-26
Biotech M&A H1 2026 Report
Read →49 deals, ~$149B in value. Q2 nearly doubled Q1. Five $10B+ takeouts, all in Q2. Lilly signed 11 deals.
29-May-26
Biotech Conference Calendar 2026
Read →Major biotech and biopharma conferences in 2026 across the US, UK, and EU, including investor events, scientific catalysts, and partnering meetings.
17-May-26
Most Active Biotech Investors 2026
Read →Ranked league table of the most active biotech and biopharma investors in 2026 by qualifying deal participation.
08-Apr-26
Biotech M&A Q1 2026 Report
Read →16 deals, $44B in value, and what the deal tape signals about where strategic buyers are paying up.
08-Jan-26
Biotech Funding Terms Glossary
Read →Plain-English definitions of the deal terms that appear in press releases, term sheets, IPOs, and M&A announcements.
07-Jan-26
2024 Biopharma M&A: Every $1B+ Deal
Read →The complete list of 2024 biopharma acquisitions worth $1B or more — public and private targets.
01-Dec-25
Top 10 BioPharma M&A Deals of 2025
Read →Ranked list of the 10 biggest biopharma and biotech acquisitions announced in 2025, with stage, therapeutic area, and investor-grade read-through.